Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

R. Ytterberg, Steven; L. Bhatt, Deepak; R. Mikuls, Ted; G. Koch, Gary; Fleischmann, R.; L. Rivas, Jose; Germino, Rebecca; Menon, Sujatha; Sun, Yanhui; Wang, Cunshan; Shapiro, Andrea; S. Kanik, Keith; A. Connell, Carol

doi:10.1056/nejmoa2109927

Public

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Published in New England Journal of Medicine • Jan 26, 2022

Authors:

Steven R. Ytterberg

Deepak L. Bhatt

Ted R. Mikuls

Abstract

BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. METHODS: We conducted a randomized, open...

View

Open Access

Subject

Tofacitinib

Rheumatoid arthritis

Medicine

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!